Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

FDA approves Teva’s generic nasal spray to treat opioid overdose

Written by: | no-reply@reuters.com | Dated: Friday, April 19th, 2019

 

(Reuters) – Generic drugmaker Teva Pharmaceutical Industries Ltd on Friday received approval from the U.S. Food and Drug Administration (FDA) to market its generic nasal spray for opioid overdose, the health regulator said.

This is the first approval of a generic naloxone nasal spray for use in a community setting by individuals without medical training, the FDA said in a statement.

Almost 400,000 people died from an opioid overdose from 1999 to 2017, the regulator said, citing data from the Centers for Disease Control and Prevention.

The FDA had tentatively approved Teva’s generic naloxone nasal spray in June last year.

 

Reporting by Ankit Ajmera in Bengaluru; Editing by Chizu Nomiyama

 

Reuters source:

https://www.reuters.com/article/us-teva-pharm-ind-generic-nasal-spray/fda-approves-tevas-generic-nasal-spray-to-treat-opioid-overdose-idUSKCN1RV15G

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom